Haypp Group Resumes Zyn Sales in the U.S.
Haypp Group is pleased to announce that it will resume U.S. sales of Zyn products in September, with direct supply from Philip Morris International. In the second quarter of 2024, Zyn accounted for 46 percent of Haypp Group’s U.S. sales.
“With consumer demand strong, we look forward to resuming sales of the leading brand Zyn in accordance with current FDA regulations” said Haypp Group CEO Gavin O’Dowd.
Haypp Group supports the FDA’s strict regulatory requirements, which include ongoing monitoring to ensure, for example, that there is no significant increase in underage usage. Such robust age verification assurance is something Haypp Group is uniquely positioned to provide in the retail landscape due to its use of leading technology and commitment to compliance.
For more information please contact:
Markus Lindblad
Head of External Affairs
+46(0)708153983
[email protected]
Erik Bloomquist
CFA, Head of Investor Relations
+44(0)7525421916
[email protected]